Historically, the values of gender-caste-based minority have been systematically excluded from even being tallied, resulting in gender-biased or gender-invisible prior statistics. The world is built on the idea that numbers can't be wrong; that data is objective and only works if it's good enough to be there. Furthermore, systems do not have their own virtuous minds. Instead, they invent an explanation depending on the information provided to them. Instead, they make up a reason based on the data that they are given. We tend to forget that these codes are based on one's own biases, experiences, and attitudes.

Posted on February 8th, 2022 by Michael F. Chiang, M.D., National Eye Institute One of many health risks premature infants face is retinopathy of prematurity (ROP), a leading cause of childhood blindness worldwide. ROP causes abnormal blood vessel growth in the light-sensing eye tissue called the retina. Left untreated, ROP can lead to lead to scarring, retinal detachment, and blindness. It's the disease that caused singer and songwriter Stevie Wonder to lose his vision. Now, effective treatments are available--if the disease is diagnosed early and accurately.

In 2021 the application of AI enabled advances in many areas of healthcare. We made significant progress in AI for drug discovery, medical imaging, diagnostics, pathology, and clinical trials. Important peer reviewed papers were published and dozens of partnerships were formed. Big Pharma companies and major tech companies became very active in the space. Record amounts of funding were raised, and a few companies even started human clinical trials. Microsoft and NVIDIA launched two of the world's most powerful supercomputers and Microsoft announced Azure OpenAI Service. In 2022 we expect these technologies to converge across the healthcare spectrum. This article summarizes milestones achieved in 2021. This is the first in a series of progress reports I'm writing on the sector that will be supplemented by industry performance data and metrics compiled in partnership with Alliance for Artificial Intelligence in Healthcare (AAIH) and other top tier resources.

From self-driving cars to virtual travel agents, artificial intelligence has quickly transformed the landscape for nearly every industry. The technology is also employed in healthcare to help with clinical decision support, imaging and triage. However, using AI in a healthcare setting poses a unique set of ethical and logistical challenges. MobiHealthNews asked health tech vet Muhammad Babur, a program manager at the Mayo Clinic, about the potential challenges and ethics behind using AI in healthcare ahead of his upcoming discussion at HIMSS22. MobiHealthNews: What are some of the challenges to using AI in healthcare? Babur: The challenges that we face in healthcare are unique and more consequential.

According to The Future Health Index 2021, the AI/ML market in healthcare is among the most promising ones. About 40% of healthcare organization leaders in different countries consider the development of the above technologies a major driver for the future sustainability of global health. Let's talk about the trends and peculiarities of implementing AI/ML-based healthcare software solutions in the US and Europe. AI/ML is applied for diagnosing, treating, and predicting diseases, as well as for carefully planning the development of individual institutions and the system as a whole. According to research by MarketsandMarkets, ML is considered a leading technology in the healthcare market.

The Food and Drug Administration issued a warning Friday to stop using the COVID-19 rapid antigen test Empowered Diagnostics CovClear and the neutralizing antibody rapid test ImmunoPass. These tests are being distributed in the U.S. with labels that show the FDA authorized them, which they did not. The FDA has concerns about the potential risk of false positives when using COVID-19 tests are not approved. They have classified the two tests as a Class I recall, which is the most serious type of recall. "These tests were distributed with labeling showing the FDA authorized them, but neither test has been authorized, cleared, or approved by the FDA for distribution or use in the United States. The FDA is concerned about the potentially higher risk of false results when using unauthorized tests," read an FDA press release.

In industries from healthcare to education to finance to manufacturing, quarantine and extended work-from-home forced companies to use technology to reimagine nearly every facet of their operations. As the world reopens in fits and starts, we analyze the industries poised to thrive in a post-Covid world. As the Covid-19 pandemic has charted its unprecedented path around the world, it's carried with it the question: What will Covid-19's legacy be? From healthcare to education to entertainment to manufacturing, technology innovators are stepping forward to help answer that question. "Crisis can be… a catalyst or can speed up changes that are on the way -- it almost can serve as an accelerant." In the wake of the outbreak, everything from doctors appointments to schooling to workouts went online. As more people have worked, learned, banked, exercised, relaxed, and even sought medical care from home during Covid-19, they have gotten a crash course in just how much can be accomplished at ...

Research into the therapeutic potential of psychedelic drugs was pioneered by psychiatrists way back in the 1950s, but the emergence of advanced technologies in pharma appears to have breathed new life into the field. As interest in the psychedelics market gains stream, a number of drug companies are now employing artificial intelligence (AI) methods in their search for new psychedelic compounds to treat a range of mental and physical conditions. One in four people in the UK will experience some kind of mental health problem every year, and figures are almost identical in the US. Despite this, treatments for psychological conditions are relatively limited – and for many patients, the drugs that are available come with side effects that negatively impact their quality of life. Psychedelics are hallucinogenic drugs that alter a person's perception and mood and affect their thought processes.

Don't miss our upcoming virtual workshop with John Snow Labs, Improve Drug Safety with NLP, to learn more about our joint NLP solution accelerator for adverse drug event detection. The World Health Organization defines pharmacovigilance as "the science and activities relating to the detection, assessment, understanding and prevention of adverse effects or any other medicine/vaccine-related problem." While all medicines and vaccines undergo rigorous testing for safety and efficacy in clinical trials, certain side effects may only emerge once these products are used by a larger and more diverse patient population, including people with other concurrent diseases. To support ongoing drug safety, biopharmaceutical manufacturers must report adverse drug events (ADEs) to regulatory agencies, such as the US Food and Drug Administration (FDA) in the United States and the European Medicines Agency (EMA) in the EU. Adverse drug reactions or events are medical problems that occur during treatment with a drug or therapy.

Elon Musk-run brain-machine interface company Neuralink is preparing to launch clinical trials that will implant brain chips in humans. Elon Musk's brain-interface technology company Neuralink may start implanting microchips in human beings from 2022. Neuralink is preparing to launch clinical trials that will implant brain chips in humans. Cofounded by Elon Musk in 2016, Neuralink is working on a chip that would be implanted in our brains to record and stimulate brain activity. This chip is being created for medical applications such as treating serious spinal cord injuries and neurological disorders.